A novel antimalarial compound from the aminopyridine class, MMV390048, becomes the first researched in Africa to enter preclinical development. In recognition of the potential of this exciting compound, the University of Cape Town (UCT) team has been awarded MMV Project of the Year 2012.

- Go to an interview [2] with Professor Kelly Chibale − Founder and Director of the University of Cape Town’s Drug Discovery and Development Centre (H3-D) and Project Leader of the UCT team that delivered MMV390048 as a preclinical candidate.

- Go to an interview [3] with Dr Cristina Donini − Associate Director, Translational Medicine, MMV; who took over as Project Director when MMV390048 was selected as a candidate.

- Go to an interview [4] with Dr Michael Witty, member of MMV's ESAC, and project mentor for MMV390048.